The Technical Analyst
Alector Inc [ALEC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Alector Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.69% $5.25
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 502.68 mill |
| EPS: | -1.560 |
| P/E: | -3.37 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 95.75 mill |
| Avg Daily Volume: | 0.685 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.37 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.57x |
| Company: PE -3.37 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.92 - 5.61 ( +/- 6.56%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-19 | Altmeyer Mark | Buy | 41 250 | Common Stock |
| 2024-03-19 | Altmeyer Mark | Buy | 19 420 | Stock Option (right to buy) |
| 2024-03-19 | Desouza Errol B | Buy | 41 250 | Common Stock |
| 2024-03-19 | Desouza Errol B | Buy | 19 420 | Stock Option (right to buy) |
| 2024-03-19 | Altmeyer Mark | Sell | 0 | No securities of the Issuer are beneficially owned. |
| INSIDER POWER |
|---|
| -15.51 |
| Last 100 transactions |
| Buy: 2 733 277 | Sell: 3 561 219 |
Forecast:
16:00 - $5.25
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.25
Forecast 2: 16:00 - $5.25
Forecast 3: 16:00 - $5.25
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.25 (-1.69% ) |
| Volume | 0.358 mill |
| Avg. Vol. | 0.685 mill |
| % of Avg. Vol | 52.33 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALEC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $6.29 | N/A | Active |
|---|
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-02-28 07:00:00 - Press Release
Alector To Participate In Upcoming Healthcare Conferences
South san francisco, calif., feb. 28, 2024 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
2024-02-27 16:05:00 - Press Release
Alector Reports Fourth Quarter And Full Year 2023 Financial Results and Provides Business Update
Data from invoke-2, evaluating the most advanced trem2 candidate in clinical development for early alzheimer's disease (ad), expected in q4 2024; trial enrollment completed in q3 2023
2024-02-20 16:05:00 - Press Release
Alector To Host Fourth Quarter And Full-year 2023 Earnings Call
Call scheduled for tuesday, february 27, 2024, at 4:30 p.m. et/1:30 p.m. pt call scheduled for tuesday, february 27, 2024, at 4:30 p.m. et/1:30 p.m. pt
2024-02-08 07:00:00 - Press Release
Alector Announces First Patient Dosed In Progress-ad Phase 2 Clinical Trial Of Al101/gsk4527226 In Patients With Early Alzheimer's Disease
The trial, being conducted in partnership with gsk, is expected to enroll approximately 282 patients globally the trial, being conducted in partnership with gsk, is expected to enroll approximately 282 patients globally
2024-02-07 07:00:00 - Press Release
Fda Grants Latozinemab Breakthrough Therapy Designation For Frontotemporal Dementia Due To A Progranulin Gene Mutation (ftd-grn)
-latozinemab is the most advanced progranulin-elevating candidate in development for ftd-grn and has now become the first investigational medicine to receive a breakthrough therapy designation for the treatment of ftd-grn-
Latest News
2024-02-27 23:23:10 - Seeking Alpha
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
2024-02-20 16:05:00 - GlobeNewsWire
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
2024-02-08 07:51:03 - Zacks Investment Research
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-01-25 13:01:05 - Zacks Investment Research
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know
Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-01-23 07:32:27 - InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.
2024-01-17 17:32:22 - Seeking Alpha
Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation
Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer's Disease. The global market for Alzheimer's Disease is expected to reach $15.5 billion by 2031.
2023-12-01 08:15:06 - MarketBeat
These biotechs targeting multiple neurodegenerative diseases
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.
2023-11-14 11:19:04 - Zacks Investment Research
Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-09-08 13:32:24 - Zacks Investment Research
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
2023-08-10 11:30:57 - Zacks Investment Research
Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.